HEPARIN SODIUM INJECTION USP SOLUTION

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

HEPARIN SODIUM

Disponibbli minn:

PFIZER CANADA ULC

Kodiċi ATC:

B01AB01

INN (Isem Internazzjonali):

HEPARIN

Dożaġġ:

1000UNIT

Għamla farmaċewtika:

SOLUTION

Kompożizzjoni:

HEPARIN SODIUM 1000UNIT

Rotta amministrattiva:

INTRAVENOUS

Unitajiet fil-pakkett:

10ML/25X10ML

Tip ta 'preskrizzjoni:

Ethical

Żona terapewtika:

HEPARINS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0104596004; AHFS:

L-istatus ta 'awtorizzazzjoni:

CANCELLED POST MARKET

Data ta 'l-awtorizzazzjoni:

2017-09-27

Karatteristiċi tal-prodott

PRODUCT MONOGRAPH
HEPARIN SODIUM INJECTION USP
FOR INTRAVENOUS OR SUBCUTANEOUS USE
1000 USP UNITS PER ML
10 000 USP UNITS PER ML
ANTICOAGULANT
Pfizer Canada Inc.
17300 Trans Canada Highway
Kirkland, Quebec
H9J 2M5
Control No.:
193940
Date of Approval: August 10, 2016
_ _
_ _
Heparin Sodium Injection_ _USP _ _
Page 2 of 25_ _
Pfizer Canada Inc.
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
.....................................................................3
INDICATIONS AND CLINICAL USE
...........................................................................3
CONTRAINDICATIONS
.................................................................................................4
WARNINGS AND PRECAUTIONS
...............................................................................4
ADVERSE REACTIONS
..................................................................................................9
DRUG INTERACTIONS
................................................................................................11
DOSAGE AND ADMINISTRATION
...........................................................................13
OVERDOSAGE
...............................................................................................................17
ACTIONS AND CLINICAL PHARMACOLOGY
......................................................17
STORAGE AND
STABILITY........................................................................................18
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................19
PART II: SCIENTIFIC INFORMATION
................................................................................20
PHARMACEUTICAL INFORMATION
......................................................................20
CLINICAL TRIALS
........................................................................................................21
REFERENCES
.........................................................